- Home
- ASRT
as 07-26-2024 4:00pm EST
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
Upcoming Earnings Alert:
Get ready for potential market movements as Assertio Holdings Inc. ASRT prepares to release earnings report on 01 Aug 2024.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | LAKE FOREST |
| Market Cap: | 113.2M | IPO Year: | 1997 |
| Target Price: | $3.44 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.73 - $5.78 | Next Earning Date: | 08-01-2024 |
| Revenue: | $142,051,000 | Revenue Growth: | -12.40% |
| Revenue Growth (this year): | -18.65% | Revenue Growth (next year): | 6.70% |
Stock Insider Trading Activity of Assertio Holdings Inc. (ASRT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mason Heather L | ASRT | Interim Executive Officer | Jun 5 '24 | Buy | $0.97 | 25,000 | $24,250.00 | 212,650 | SEC Form 4 |
| Tyree James L | ASRT | Director | Mar 14 '24 | Sell | $1.12 | 10,251 | $11,462.67 | 188,251 | SEC Form 4 |
Latest Assertio Holdings Inc. News
ASRT Breaking Stock News: Dive into ASRT Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Assertio Holdings, Inc. to Report Second Quarter 2024 Financial Results on August 7, 2024
GlobeNewswire
17 days ago
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Simply Wall St.
22 days ago
Assertio Holdings (NASDAQ:ASRT) adds US$14m to market cap in the past 7 days, though investors from five years ago are still down 89%
ACCESSWIRE
a month ago
Sidoti Events, LLC's Virtual June Small-Cap Conference
GlobeNewswire
2 months ago
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
Assertio to Participate in the Sidoti Small Cap Conference on June 12, 2024
MT Newswires
2 months ago
Assertio Therapeutics Names Brendan O'Grady as Chief Executive
GlobeNewswire
2 months ago
Assertio Announces the Appointment of Brendan P. O’Grady as New CEO
Compare ASRT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ASRT Assertio Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.